Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

ClinicalTrials.gov ID: NCT00775463

Public ClinicalTrials.gov record NCT00775463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.

Study identification

NCT ID
NCT00775463
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
United Therapeutics
Industry
Enrollment
148 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2009
Primary completion
Feb 28, 2011
Completion
Jun 30, 2011
Last update posted
Dec 27, 2023

2009 – 2011

United States locations

U.S. sites
24
U.S. states
21
U.S. cities
24
Facility City State ZIP Site status
University of Alabama - Arthritis Clinical Intervention Program Birmingham Alabama 35294
Mayo Clinic Scottsdale Scottsdale Arizona 85259
UCLA Los Angeles California 90095
Stanford University School of Medicine/Palo Alto VA Health Care System Palo Alto California 94304
Denver Medical Center Aurora Colorado 80045
University of Connecticut Health Center Farmington Connecticut 06030
Georgetown University Washington D.C. District of Columbia 20007
Northwestern University - Feinberg School of Medicine Chicago Illinois 60611
University of Indiana School of Medicine Indianapolis Indiana 46202
Johns Hopkins University - Division of Rheumatology Baltimore Maryland 21224
Boston University School of Medicine Boston Massachusetts 02118
University of Michigan Scleroderma Program Ann Arbor Michigan 48106
University of Minnesota Minneapolis Minnesota 55455
UMDNJ Clinical Research Center New Brunswick New Jersey 08903
North Shore-LIJ Health System Lake Success New York 11042
The Hospital for Special Surgery New York New York 10021
Cleveland Clinic Foundation Cleveland Ohio 44195
University of Toledo Toledo Ohio 43614
University of Pittsburgh Pittsburgh Pennsylvania 15261
Medical University of South Carolina Charleston South Carolina 29425
University of Texas - Houston Houston Texas 77030
University of Utah Salt Lake City Utah 84132
Virginia Mason Medical Center Seattle Washington 98111
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00775463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 27, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00775463 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →